Gemeinsamkeiten und Unterschiede der primären Radiotherapie beim lokalisierten und lokal fortgeschrittenen Prostatakarzinom in der Schweiz : Eine Analyse der der Behandlungskonzepte Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland : A survey on patterns of practice.

Details

Serval ID
serval:BIB_90BE0A0F0301
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Gemeinsamkeiten und Unterschiede der primären Radiotherapie beim lokalisierten und lokal fortgeschrittenen Prostatakarzinom in der Schweiz : Eine Analyse der der Behandlungskonzepte Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland : A survey on patterns of practice.
Journal
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al]
Author(s)
Panje C.M., Dal Pra A., Zilli T., R Zwahlen D., Papachristofilou A., Herrera F.G., Matzinger O., Plasswilm L., Putora P.M.
ISSN
1439-099X (Electronic)
ISSN-L
0179-7158
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
191
Number
10
Pages
778-786
Language
english
Notes
Publication types: ARTICLE
Publication Status: ppublish
Abstract
INTRODUCTION: External beam radiotherapy (EBRT), with or without androgen deprivation therapy (ADT), is an established treatment option for nonmetastatic prostate cancer. Despite high-level evidence from several randomized trials, risk group stratification and treatment recommendations vary due to contradictory or inconclusive data, particularly with regard to EBRT dose prescription and ADT duration. Our aim was to investigate current patterns of practice in primary EBRT for prostate cancer in Switzerland.
MATERIALS AND METHODS: Treatment recommendations on EBRT and ADT for localized and locally advanced prostate cancer were collected from 23 Swiss radiation oncology centers. Written recommendations were converted into center-specific decision trees, and analyzed for consensus and differences using a dedicated software tool. Additionally, specific radiotherapy planning and delivery techniques from the participating centers were assessed.
RESULTS: The most commonly prescribed radiation dose was 78 Gy (range 70-80 Gy) across all risk groups. ADT was recommended for intermediate-risk patients for 6 months in over 80 % of the centers, and for high-risk patients for 2 or 3 years in over 90 % of centers. For recommendations on combined EBRT and ADT treatment, consensus levels did not exceed 39 % in any clinical scenario. Arc-based intensity-modulated radiotherapy (IMRT) is implemented for routine prostate cancer radiotherapy by 96 % of the centers.
CONCLUSION: Among Swiss radiation oncology centers, considerable ranges of radiotherapy dose and ADT duration are routinely offered for localized and locally advanced prostate cancer. In the vast majority of cases, doses and durations are within the range of those described in current evidence-based guidelines.
Pubmed
Web of science
Create date
03/07/2015 11:28
Last modification date
20/08/2019 15:54
Usage data